Patents by Inventor AURELIEN JACOB

AURELIEN JACOB has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transient inhibition of p53 in gene therapy
    Patent number: 12558435
    Abstract: An agent which promotes homology directed DNA repair for use in haematopoietic stem and/or progenitor cell gene therapy, wherein said haematopoietic stem cells are gene edited. Use of an agent which promotes homology directed DNA repair, for increasing the survival and/or engraftment of gene edited haematopoietic stemand/or progenitorcells or for increasing the efficiency of gene editing of haematopoietic stem and/or progenitor cells.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: February 24, 2026
    Assignees: Ospedale San Raffaele S.R.L., Fondazione Telethon ETS
    Inventors: Pietro Genovese, Giulia Schiroli, Luigi Naldini, Aurelien Jacob, Samuele Ferrari
  • Gene Therapy
    Publication number: 20250288617
    Abstract: Use of a combination of (a) cyclosporin H (CsH) or a derivative thereof, and (b) a p53 inhibitor and/or an adenoviral protein, or one or more nucleotide sequences encoding therefor, for increasing the efficiency of gene editing of an isolated population of cells when transduced by a viral vector and/or increasing the efficiency of transduction of an isolated population of cells by a viral vector.
    Type: Application
    Filed: April 28, 2023
    Publication date: September 18, 2025
    Inventors: Samuele Ferrari, Aurelien Jacob, Luigi Naldini
  • GENE THERAPY
    Publication number: 20210260216
    Abstract: An agent which promotes homology directed DNA repair for use in haematopoietic stem and/or progenitor cell gene therapy, wherein said haematopoietic stem cells are gene edited. Use of an agent which promotes homology directed DNA repair, for increasing the survival and/or engraftment of gene edited haematopoietic stemand/or progenitorcells or for increasing the efficiency of gene editing of haematopoietic stem and/or progenitor cells.
    Type: Application
    Filed: June 25, 2019
    Publication date: August 26, 2021
    Inventors: Pietro Genovese, Giulia Schiroli, Luigi Naldini, Aurelien Jacob, Samuele Ferrari
  • Baculovirus system for the expression of a gene therapy vector
    Patent number: 10767192
    Abstract: The invention relates to a recombinant baculoviral genome useful for the production of viral vectors for gene therapy, allowing said production from a single infection.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: September 8, 2020
    Assignee: GENETHON
    Inventors: Lionel Galibert, Otto-Wilhelm Merten, Aurelien Jacob
  • BACULOVIRUS SYSTEM FOR THE EXPRESSION OF A GENE THERAPY VECTOR
    Publication number: 20180305717
    Abstract: The invention relates to a recombinant baculoviral genome useful for the production of viral vectors for gene therapy, allowing said production from a single infection
    Type: Application
    Filed: July 9, 2018
    Publication date: October 25, 2018
    Inventors: LIONEL GALIBERT, OTTO-WILHELM MERTEN, AURELIEN JACOB